CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions

Abstract Background Interleukin (IL)-23 neutralizing antibodies are clinically efficacious but differ in the functionality of their Fc portion. Guselkumab (GUS) and ustekinumab (UST) have a wild-type (WT) Fc portion, permitting native binding to Fc gamma receptors (FcγRs), while risankizumab (RZB) l...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Joel F. Cohen-Solal, Calvin S. Pohl, Sheila M. Cummings, Jeremy P. Gygi, Zhaleh Safikhani, Brigitte Bartocha, Christopher D. Buckley, Yongli Dong, Killian Eyerich, Samuel D. Karsen, Grace R. Lynch, Michael Macoritto, Pierre A. Morisset, Ornella D. Nelson, Timothy Radstake, Florian Rieder, Jocelyn Rivas, John P. Savaryn, Kathleen M. Smith, Madison Stulir, Carmin Szynal, Casey Tylek, Geertruida M. Veldman, Laura G. Wasserman, Susan Westmoreland, Neha Chaudhary, Matthew M. Staron
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2026-03-01
Σειρά:	Molecular Medicine
Θέματα:	CD64 Crohn’s disease Fc portion FcγRI Guselkumab Inflammatory bowel disease
Διαθέσιμο Online:	https://doi.org/10.1186/s10020-026-01462-z
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!